title: New surgery for better outcomes: shaping the field of congenital heart disease.
abstract: BACKGROUND
  The field of congenital heart disease is constantly evolving through better understanding of the disease itself, albeit its history, prevalence, genetics, and follow-up. Concurrently surgical techniques and approaches have been developed, modified, and refined.
  
  
  METHODS
  The impact of interventional pediatric cardiology has been dramatic. The field of catheter-based therapies has exploded with the first pulmonary valve balloon angioplasty in 1982. With evolving stent technology, they are now used in multiple areas, including pulmonary arteries, vena cavae, aortic and arch and descending aorta for coarctation. The hybrid surgery concept involves a multidisciplinary team of interventional cardiologist and surgeon combining catheter-intervention and surgery in the surgical theater such as pulmonary artery stent implantation associated with pulmonary valve replacement. Furthermore, in selected cases, pulmonary valve device implantation is becoming an accepted approach to a surgical problem.
  
  
  RESULTS
  Balloon angioplasties, stent implantations, hybrid surgeries and pulmonary valve device implantation are performed with a very low mortality and morbidity. The risks and benefits outweigh the ones associated to surgical procedures.
  
  
  CONCLUSIONS
  With fast developing interventional therapies, the work of pediatric cardiologists and cardiac surgeons is more intertwined than ever in search of better outcomes for the children with congenital heart disease.
authors.affiliation: British Columbia Children's Hospital, 4480 Oak Street, Suite AB307, Vancouver, BC, V6H 3V4, Canada. jleblanc@cw.bc.ca
authors.forename: Jacques G
authors.initials: JG
authors.lastname: Leblanc
mesh_terms: D006328:Cardiac Catheterization; D006348:Cardiac Surgical Procedures / Q000639:trends*; D002648:Child; D004151:Dipeptides; D006330:Heart Defects, Congenital / Q000601:surgery*; D006801:Humans; D018636:Hypoplastic Left Heart Syndrome / Q000601:surgery; D011664:Pulmonary Valve / Q000601:surgery; D012086:Reoperation; D015607:Stents; D013844:Thiazoles; D016896:Treatment Outcome
chemical_list: C540947:3-methoxy-2-(3-methoxy-2-((2-methyl-1,3-thiazol-5-yl)formamido)propanamido)-N-(1-(2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)propanamide; D004151:Dipeptides; D013844:Thiazoles
references.citation: Circulation. 2003 May 6;107(17):2168-70
references.pmid: 12732590
references.citation: Surgery. 1955 Jul;38(1):11-29
references.pmid: 14396676
references.citation: JAMA. 1966 Jun 13;196(11):991-2
references.pmid: 4160716
references.citation: N Engl J Med. 1983 Jan 6;308(1):23-6
references.pmid: 6847920
references.citation: N Engl J Med. 1982 Aug 26;307(9):540-2
references.pmid: 7099226
references.citation: Pediatr Cardiol. 2005 Jul-Aug;26(4):315-22
references.pmid: 16374678
references.citation: Eur J Cardiothorac Surg. 2005 Apr;27(4):544-7
references.pmid: 15784348
references.citation: Ann Cardiol Angeiol (Paris). 1979 Dec;28(7):487-9
references.pmid: 551743
references.citation: Eur J Cardiothorac Surg. 2005 Apr;27(4):536-43
references.pmid: 15784347
references.citation: J Am Coll Cardiol. 2002 May 15;39(10):1664-9
references.pmid: 12020495